Evogene and biogemaa are engaging in a multiyear collaboration project to deliver corn varieties with improved tolerance to abiotic stress (mainly drought resistance) using gene constructs which have been demonstrated in other plants.
Delfia kits for 1st trimester preeclampsia (5-7% of pregnancies) tests will be developed with europium fluorometry & computerised robotic arms for accurate & fast testing. Verified clinically, and fda & ce registered, the kit will improve patient access & enhance sales for women's health.
Personalised medicine has been targeted as the most important future development in both medicine and drug development. The final product that synergistically combines the two companies' capabilities will be a software platform.
The diagnostic system is a fluorescent-based, microsphere assay using flow cytometry detection and analysis to identify viral proteases in biological samples
Increasing the bioavailability and targeted delivery of active ingredients - curcumin.
An innovative lipid emulsion that provides in a single lipid all the necessary fatty acids in correct amounts and ratios, specifically tailored to the neonate's needs. By providing a balanced and complete parenteral nutrition for neonates, it will reduce the risks of complications.
The oral cavity is a unique organ and an entry gate to the whole body. The oralgerd project aims at developing a generic electronic intra-oral technological platform attached to a tooth for various applications such as gerd diagnostics, drug delivery, body health monitoring, and more.
Human recombinant fsh will be expressed in engineered yeast cells and purified to homogeneity to meet fsh quality currently marketed. The unique feature of the project is a cost-effective process of human glycosylation and sialylation of fsh, driven by human genes, in a non-human organism.
A recombinant protein purification platform based on cim(r) convective interaction media monolith technology will be developed to significantly decrease protein purification time and costs. The project will result in novel, technical, superior products and services and lower production costs.
Development of rapamycin eluting stents based on crystallization of the drug onto stent surface aims to develop a crystalline carrier-free coating of rapamycin onto stents which will keep the original metallic stent in the body after the drug has been released